CompletedNCT01730768

AQW051 Compared With Placebo for Thinking Skills in Schizophrenia

About this title

A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

Medication studyAges 18–55United States

The study in practice

Understand this study

Listed age limits: 18 years to 55 years.

Listed locations: Garden Grove and 12 more locationsSee all locations and recruitment
Study phase: Phase 2

Study clarity

Study start dateSeptember 2012

Recruitment status: Completed
Enrollment listed in the registry: 147
Sponsor: Novartis Pharmaceuticals
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT01730768
Official title: Show the full official title
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

Completed

Garden Grove · Glendale · National City

9 more locations

FAQ

Who is behind this study?

The study sponsor is Novartis Pharmaceuticals.

Did this study involve medication?

Yes. The study involved medication, including AQW051 and Placebo.

Who was this study for?

Listed age limits: 18 years to 55 years.